Abstract

Acute lymphoblastic leukemia (ALL), is a biologically heterogeneous disease where diagnosis, treatment and prognosis is heavily dependent on the correct characterization of the immunophenotype of each case. To describe the immunophenotypic and laboratory features of a cohort of Sri Lankan children and adults with ALL and to compare them with those reported in other series. Records of 229 patients who were suspected of having acute leukaemia and referred for flow cytometry to the Asiri Hospital Sri Lanka, between August 2009 and October 2013 were reviewed. Referrals were from across the country including the National Cancer Institute. Sixty seven percent were children below 12 years of age. 80% had B-lymphoblastic leukaemia (B-ALL), 20% T- lymphoblastic leukaemia (T-ALL). In children, the peak age of diagnosis was between 2-6 years in B-ALL (61%) and 3-6 years (43.7%) in T-ALL. Incidence was commoner in males in all age groups and subtypes except in the adult B ALL group where the incidence was equal. Ninety three percent of paediatric B-ALL and 67% adult B-ALL were CD10 positive common ALL. In T-ALL cytoplasmic expression of CD3 was 100%. nTdT was the most commonly expressed immature marker, in B-ALL - 91% and in T-ALL- 69%. At least one myeloid antigen was present in 34% of B-ALL cases and 60% of T-ALL cases. This study represents the first immunophenotype based description of ALL in Sri Lanka. Age, sex distribution, ALL subtypes and the immunophenotypic profile of each subtype mirrored those of previous studies.

Highlights

  • Sex distribution, Acute lymphoblastic leukemia (ALL) subtypes and the immunophenotypic profile of each subtype mirrored those of previous studies

  • Acute lymphoblastic leukemia (ALL), a neoplasm of precursor cells committed to B or T cell lineage has a world wild incidence of 1-4.75/100000 persons per year [1,2]

  • As of to date there is a lack of published data on ALL based on this classification in Sri Lanka

Read more

Summary

Introduction

Acute lymphoblastic leukemia (ALL), a neoplasm of precursor cells committed to B or T cell lineage has a world wild incidence of 1-4.75/100000 persons per year [1,2]. ALL is a biologically heterogeneous disease with clinical features, morphology, immunophenotype, cytogenetic and molecular genetic abnormalities having important implications in the diagnosis, classification, risk stratification, minimal residual disease analysis and prognosis. This was highlighted with the introduction of the WHO system of classification of haemopoetic neoplasms that replaced the purely cytomorphology and cytochemistry based French and British system [2]. Acute lymphoblastic leukemia (ALL), is a biologically heterogeneous disease where diagnosis, treatment and prognosis is heavily dependent on the correct characterization of the immunophenotype of each case

Objectives
Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.